+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 85Years
All Genders
ID07746687

Evaluating the Safety and Effectiveness of JNJ-95597528 Compared to Placebo in Adults with Moderate to Severe Asthma Not Adequately Controlled

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

440

Participants Needed

19

Research Sites

41 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well JNJ-95597528 works compared to a placebo in adults with moderate to severe asthma that is not adequately controlled. This Phase 2b trial aims to assess the treatments effects on reducing asthma exacerbations and improving lung function, focusing on participants who have been on stable inhaled corticosteroid and additional asthma controller medications. Participants will be randomly assigned to one of four groups three different dosing schedules of JNJ-95597528 or a matching placebo. The study drug and placebo are given via subcutaneous injection at specific weeks 0, 2, 12, 24, and 36, depending on the group. The trial is double-blind and placebo-controlled to compare safety and efficacy. During the study, participants will be monitored through regular visits up to 48 weeks to measure asthma exacerbations, lung function tests such as forced expiratory volume, exhaled nitric oxide levels, and asthma control questionnaires. Safety will be assessed by tracking adverse events up to 90 weeks. The study involves multiple scheduled doses and ongoing assessments to evaluate treatment response and safety over time.

CONDITIONS

Brief Title

A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here